Syndax Pharmaceuticals, Inc.
NASDAQ:SNDXBiotechnology
+$0.13 today
- Market cap
- $770.64M
- Beta
- 0.39
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$2.81
Volume 3.46M
Average 1.70M
SNDX Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Syndax Pharmaceuticals, Inc.NASDAQ: SNDX
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow declines year over year
Q1 FY2026 free cash flow of $50.35M (cash outflow) fell 47.1% year over year, behind the -2.9% change in trailing-twelve-month free cash flow. Sequentially, it fell 27.6% from the prior quarter. Over 3 fiscal years it compounded at +34.1% a year.
Context
- Free cash flow amounted to 187.5% of revenue in FY2025, down 973.4 pp from a year earlier.
- Free cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -47.1% toward the trailing-twelve-month pace of -2.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (323.17M) USD
- Year-over-year change
- -17.6%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (323.17M) | -17.6% |
| FY2024 | 2024-12-31 | (274.9M) | -71.2% |
| FY2023 | 2023-12-31 | (160.6M) | -19.9% |
| FY2022 | 2022-12-31 | (133.9M) | -561.7% |
| FY2021 | 2021-12-31 | 29M | — |
Free Cash Flow vs competitors
How SNDX compares with its peers on the latest reported figures
- SNDX's LTM Mar 2026 free cash flow of $278.35M is the 4th largest of the 11 companies compared; the peer median is $97.04M.
- Its year-over-year change of -2.9% is the 8th highest of 11, against a peer median of +19.0%.
- Free cash flow amounts to 128.2% of revenue for SNDX, versus a peer median of 52.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $475M | +38.9% | — | 406.0% | |
| LTM Aug 2026 | $369.81M | +253.2% | +15.3% | 52.7% | |
| LTM Dec 2025 | $283.27M | +47.6% | +33.0% | — | |
| LTM Mar 2026 | $278.35M | -2.9% | +34.1% | 128.2% | |
| LTM Jun 2026 | $208.29M | +47.9% | +94.1% | 198.4% | |
| LTM Sep 2026 | $112.33M | +69.7% | — | 42.2% | |
| LTM Mar 2026 | $111.36M | -4.5% | +13.9% | — | |
| LTM Jun 2026 | $82.72M | -50.9% | +21.7% | 48.7% | |
| LTM Mar 2026 | $80.19M | -1.7% | -12.3% | 225.6% | |
| LTM Mar 2026 | $78.33M | -28.1% | -2.4% | — | |
| LTM Mar 2026 | $71.69M | -1.0% | -2.9% | 45.6% | |
| Peer median (excluding SNDX) | $97.04M | +19.0% | +14.6% | 52.7% | |
Competitors are the stored peer set for SNDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 24.93M | (149.34M) | (209.36M) | (318.76M) | (285.42M) |
| Depreciation & Amortization | 43K | 33K | 12K | 8K | 6K |
| Deferred Income Tax | 255K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.32M | 16.02M | 30.95M | 43.03M | 47.5M |
| Change in Working Capital | (9.6M) | 1.66M | 31.86M | 13.27M | (79.32M) |
| Accounts Receivables | 0 | (3.47M) | 10.71M | (11.24M) | (36.83M) |
| Inventory | 0 | 3.47M | 0 | (366K) | (32.09M) |
| Accounts Payables | 2.16M | (1.32M) | 5.61M | 1.67M | 4.95M |
| Other Working Capital | (11.76M) | 2.98M | 15.54M | 23.21M | (15.35M) |
| Other Non-Cash Items | 187K | (2.05M) | (14.06M) | (12.45M) | (5.75M) |
| Operating Cash Flow | 29.13M | (133.68M) | (160.6M) | (274.9M) | (322.98M) |
| Capital Expenditures | (129K) | (225K) | 0 | 0 | (187K) |
| Acquisitions (Net) | 40.74K | 225K | 0 | 0 | 0 |
| Purchases of Investments | (294.72M) | (495.35M) | (354.61M) | (557.05M) | (195.81M) |
| Sales of Investments | 253.98M | 308.93M | 472.22M | 337.28M | 486.03M |
| Other Investing Activities | (40.74K) | 225K | 0 | 0 | 0 |
| Investing Cash Flow | (40.87M) | (186.19M) | 117.61M | (219.78M) | 290.04M |
| Debt Repayment | 0 | (21M) | 0 | 0 | 0 |
| Common Stock Issued | 86.34M | 181.39M | 258.09M | 9.72M | 13.68M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 32.13M | 11.86M | 6.04M | 343.65M | 0 |
| Financing Cash Flow | 118.46M | 172.25M | 264.13M | 353.37M | 13.68M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 106.72M | (147.61M) | 221.14M | (141.31M) | (19.27M) |
| Free Cash Flow | 29M | (133.9M) | (160.6M) | (274.9M) | (323.17M) |
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
Intrinsic Alpha fair value
Locked
Current Price
$8.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.